Scope Fit (cc-scope-fit)
When to trigger
- Starting a project and unsure if Cancer Cell is the right venue
- A reviewer or PI says "this feels incremental" or "too descriptive"
- Considering a Cell Press presubmission inquiry
- Deciding between Cancer Cell and a broader-scope or specialty journal
What Cancer Cell wants
Cancer Cell publishes mechanistic, hypothesis-driven cancer biology and translational oncology. The recurring acceptance pattern combines two pillars:
- Mechanistic depth — a defined molecular mechanism (a pathway, regulatory axis, genetic/epigenetic event, or cell-cell interaction), not just a phenotype or a correlation.
- Translational relevance — the mechanism matters for human cancer: it is anchored in patient data, predicts a vulnerability, or motivates a therapeutic / biomarker strategy.
In-scope topics include tumor biology and signaling, cancer genetics / genomics, the tumor microenvironment, immuno-oncology, metastasis, therapy resistance, and clinical-translational studies that carry mechanistic insight.
Fit decision table
| Signal in the manuscript |
Fit verdict |
| Clear mechanism + validated in cells, in vivo, AND human/patient data |
Strong fit |
| Mechanism + in vivo, human data is associative but supportive |
Likely fit — strengthen human anchor |
| Mechanism only in cell lines, no in vivo, no human relevance |
Off-fit — go back to cc-study-design |
| Descriptive omics / atlas with no mechanism or vulnerability |
Off-fit unless reframed around a mechanism |
| Strong clinical correlation but no mechanism |
Off-fit — likely a specialty / clinical journal |
| Methods / tool paper without a cancer-biology discovery |
Off-fit — a methods journal |
| Therapeutic claim with only in vitro support |
Premature — needs in vivo / human validation |
How to position the contribution
- State the gap in mechanistic understanding, not just "X is understudied."
- Name the orthogonal systems that will close it (cells + in vivo + human).
- Make the translational hook explicit and proportionate to the evidence (mechanism → vulnerability → candidate intervention/biomarker).
- Compare to the closest 2–3 prior papers and say precisely what is new (new mechanism, new node, new context, new in vivo proof).
Presubmission inquiry decision gate
For a borderline paper, reduce the decision to three evidence questions before investing in a full
Cancer Cell package:
| Question |
Strong answer |
Weak answer |
| Mechanism |
The causal molecular axis is perturbed, rescued, and connected to phenotype. |
The axis is inferred from correlation or omics enrichment only. |
| Human anchor |
Patient samples, clinical dataset, organoid, or translational model supports relevance. |
Only immortalized cell-line evidence or an anecdotal clinical correlation. |
| Therapeutic/biomarker logic |
The intervention, vulnerability, or stratification claim follows from the mechanism. |
Translational language is aspirational and not tested. |
If one column is weak, the best next move is usually cc-study-design, not cover-letter polish. If all
three are strong, a presubmission inquiry can emphasize the mechanism, the human anchor, and the exact
delta over the nearest Cancer Cell or Cell Press papers.
Checklist
Anti-patterns
- A single-system (cell-line-only) story pitched as a major mechanism
- Descriptive single-cell / genomic atlas with no functional mechanism or vulnerability
- "Therapeutic target" framing with no in vivo efficacy or human evidence
- Overclaiming clinical impact from a correlation
- Repackaging an incremental extension of the lab's prior paper without a new mechanistic node
Output format
【Scope verdict】Strong fit / Likely fit / Off-fit
【Mechanism (1 sentence)】...
【Orthogonal validation present】cells / in vivo / human — list which
【Translational hook】... (and whether evidence supports it)
【Gap vs. closest prior work】...
【Next step】Strengthen via cc-study-design / proceed to cc-study-design / reconsider venue
Source: brycewang-stanford/Awesome-Journal-Skills → Cancer-Cell-Skills/skills/cc-scope-fit/SKILL.md
1---2name: cc-scope-fit3description: Use when deciding whether a molecular / translational oncology study belongs in Cancer Cell (Cell Press) before investing in full submission. Diagnoses mechanism + translational-relevance fit; it does not design experiments or edit prose.4---5
6
7# Scope Fit (cc-scope-fit)
8
9## When to trigger
10
11- Starting a project and unsure if Cancer Cell is the right venue
12- A reviewer or PI says "this feels incremental" or "too descriptive"
13- Considering a Cell Press presubmission inquiry
14- Deciding between Cancer Cell and a broader-scope or specialty journal
15
16## What Cancer Cell wants
17
18Cancer Cell publishes mechanistic, hypothesis-driven cancer biology and translational oncology. The recurring acceptance pattern combines **two pillars**:
19
201. **Mechanistic depth** — a defined molecular mechanism (a pathway, regulatory axis, genetic/epigenetic event, or cell-cell interaction), not just a phenotype or a correlation.
212. **Translational relevance** — the mechanism matters for human cancer: it is anchored in patient data, predicts a vulnerability, or motivates a therapeutic / biomarker strategy.
22
23In-scope topics include tumor biology and signaling, cancer genetics / genomics, the tumor microenvironment, immuno-oncology, metastasis, therapy resistance, and clinical-translational studies that carry mechanistic insight.
24
25## Fit decision table
26
27| Signal in the manuscript | Fit verdict |
28|-----------------------------------------------------------------------|--------------------------------------|
29| Clear mechanism + validated in cells, in vivo, AND human/patient data | Strong fit |
30| Mechanism + in vivo, human data is associative but supportive | Likely fit — strengthen human anchor |
31| Mechanism only in cell lines, no in vivo, no human relevance | Off-fit — go back to `cc-study-design` |
32| Descriptive omics / atlas with no mechanism or vulnerability | Off-fit unless reframed around a mechanism |
33| Strong clinical correlation but no mechanism | Off-fit — likely a specialty / clinical journal |
34| Methods / tool paper without a cancer-biology discovery | Off-fit — a methods journal |
35| Therapeutic claim with only in vitro support | Premature — needs in vivo / human validation |
36
37## How to position the contribution
38
39- State the **gap** in mechanistic understanding, not just "X is understudied."
40- Name the **orthogonal systems** that will close it (cells + in vivo + human).
41- Make the **translational hook** explicit and proportionate to the evidence (mechanism → vulnerability → candidate intervention/biomarker).
42- Compare to the closest 2–3 prior papers and say precisely what is new (new mechanism, new node, new context, new in vivo proof).
43
44## Presubmission inquiry decision gate
45
46For a borderline paper, reduce the decision to three evidence questions before investing in a full
47Cancer Cell package:
48
49| Question | Strong answer | Weak answer |
50|----------|---------------|-------------|
51| Mechanism | The causal molecular axis is perturbed, rescued, and connected to phenotype. | The axis is inferred from correlation or omics enrichment only. |
52| Human anchor | Patient samples, clinical dataset, organoid, or translational model supports relevance. | Only immortalized cell-line evidence or an anecdotal clinical correlation. |
53| Therapeutic/biomarker logic | The intervention, vulnerability, or stratification claim follows from the mechanism. | Translational language is aspirational and not tested. |
54
55If one column is weak, the best next move is usually `cc-study-design`, not cover-letter polish. If all
56three are strong, a presubmission inquiry can emphasize the mechanism, the human anchor, and the exact
57delta over the nearest Cancer Cell or Cell Press papers.
58
59## Checklist
60
61- [ ] One sentence states the mechanism (molecule/axis → effect on cancer phenotype)
62- [ ] Mechanism is validated in ≥2 orthogonal systems, ideally including human/patient data
63- [ ] Translational relevance is explicit and matched to the evidence level
64- [ ] Closest prior work is identified; the advance over it is specific
65- [ ] The study is hypothesis-driven, not purely descriptive
66- [ ] Therapeutic / biomarker claims are backed by in vivo and/or human data
67- [ ] If a clinical-trial-style study, mechanism still carries the novelty
68
69## Anti-patterns
70
71- A single-system (cell-line-only) story pitched as a major mechanism
72- Descriptive single-cell / genomic atlas with no functional mechanism or vulnerability
73- "Therapeutic target" framing with no in vivo efficacy or human evidence
74- Overclaiming clinical impact from a correlation
75- Repackaging an incremental extension of the lab's prior paper without a new mechanistic node
76
77## Output format
78
79```
80【Scope verdict】Strong fit / Likely fit / Off-fit
81【Mechanism (1 sentence)】...
82【Orthogonal validation present】cells / in vivo / human — list which
83【Translational hook】... (and whether evidence supports it)
84【Gap vs. closest prior work】...
85【Next step】Strengthen via cc-study-design / proceed to cc-study-design / reconsider venue
86```
87
88---
89
90**Source:** [`brycewang-stanford/Awesome-Journal-Skills`](https://github.com/brycewang-stanford/Awesome-Journal-Skills) → `Cancer-Cell-Skills/skills/cc-scope-fit/SKILL.md`
thedixitjain